Dalip Sethi

Hudson Respiratory Care, Inc. manufactures disposable respiratory care and anesthesia products. Its products include endotracheal tubes, anesthesia breathing circuits, masks, hygroscopic condenser humidifiers, bacteria, viral filters and gas sampling. The company was founded in 1945 and is headquartered in Morrisville, NC.

Mylan Specialty LP develops, manufactures, and markets respiratory disease & allergy treatment products. The company was founded in 1978 and is headquartered in Morgantown, WV.

Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY.

University of Southern California is a private research university that mainly offers undergraduate, graduate & other higher education. The university was founded in 1880 and is headquartered in Los Angeles, CA.

TotipotentRX Corp. is engaged in the research, development, and commercialization of cell-based therapeutics for use in regenerative medicine. They operate three distinct businesses to serve patients, physicians and partners: Therapeutics Division, Contract Services Division, Cell Manufacturing and Banking Division. Therapies: They lead therapeutic technology platform, TotiCell™ (an intraoperative rapid system for harvesting, preparing, testing, and delivering a therapeutic dose of autologous bone marrow derived or peripheral blood derived cells and proteins), is currently in varying stages of Phase 1b trials as a potential treatment for acute myocardial infarction, critical limb ischemia, non-healing ulcers and osteoarthritis. Their patented therapies are designed for rapid (under 60 minute) use at the bedside and per U.S. regulations include all integrated equipment, diagnostics, devices, and software to produce the specified autologous therapeutic cell dose. Contract Trial Services: TotipotentRX's clinical research organization is the only specialized cell therapy CRO globally.They leverage the company's unique expertise in designing, managing, and completing cell based clinical trials including the ability to support various device prototyping and validation typically required in a combination product. Their full service cellular biologicals and medical devices services include clinical study design, cost effective contract Phase I-II clinical trials, regulatory consultation, physician training and support for cellular product oversight, handling and delivery of the cellular therapy, and fully validated laboratory services for cellular bioanalytics. The services offered ensure patient safety under Good Clinical Practices (GCP), quality laboratory documentation under Good Laboratory Practices (GLP), and quality cell processing and handling under both Good Manufacturing Practices (GMP) and Good Tissue Practices (GTP). In partnership with Fortis Healthcare they have assembled the industry's most experienced cell therapy CRO team to execute at every level of their client's clinical trial, providing complete and seamless cellular drug and device clinical services. TotipotentRX brings its expertise in medical management, cellular manufacturing, and regulatory affairs to any project in regenerative medicine. Cell Manufacturing and Banking Services: The Company operates advanced clinical cell manufacturing, processing, testing, and storage facilities compliant with Good Manufacturing Practices, Good Tissue Practices, and Good Laboratory Practices. They can support the production of a personalized medicine prescription or a large scale batch process. Patient samples, batch samples, and therapeutic aliquots are all labeled per ISBT 128 and stored in its long term cryogenics facility.

OxOnc Development LP operates as an oncology development company. It offers a drug development model that is based on the expertise and core competencies to design and execute clinical trials in oncology. The firm's business model is an integration of scientific, clinical, operational and financial resources, and provides a value-add proposition to its co-development partner by providing a profit and loss-sparing mechanism to fund research and development efforts externally. The company was founded in 2012 and is headquartered in George Town, Cayman Islands.

Boyalife Group Co. Ltd. engages in drug innovation and biological research. It offers stem cell and genomics services. The company was founded by Xiaochun Xu and Lisa Li in 2009 and is headquartered in Wuxi, China.

California Institute of Technology provides education focusing on science, engineering, academia, business, and public service. The company was founded in 1891 and it is headquartered in Pasadena, CA.

Lavipharm Corp. manufactures and distributes pharmaceutical and cosmetic products. It develops drugs for the cardiology, central nervous system, gastrointestinal system, and dermatological treatment. The company was founded in 1979 and is located in East Windsor, NJ.

Minaris Regenerative Medicine LLC provides cell therapy services. It provides contract development and manufacturing organization (CDMO) services at current Good Manufacturing Practices (cGMP) standards, including clinical manufacturing, commercial manufacturing, and manufacturing development. The company was founded by Robert A. Preti and Andrew L. Pecora in 1997 and is headquartered in Allendale, NJ.

The National Centre for Biological Sciences (NCBS) is a research institute located in Bangalore, IN. The Tata Institute for Genetics and Society (TIGS) is a non-profit research institute that aspires to develop solutions to challenges in human health and agriculture using applications of cutting-edge science and technology in genetics and genomics. The NCBS conducts research on various topics such as the assembly of mixed and branched heterotypic ubiquitin chains, evolution, and dopamine-neuropeptide axis maintenance in Drosophila. The institute has also been involved in tracking COVID and dengue through sewage surveillance. The institute is part of the Tata Institute of Fundamental Research and is dedicated to the study of stem cell and regenerative biology. The center for cellular and molecular platforms (C-CAMP) is an initiative of the Department of Biotechnology, Ministry of Science and Technology, with a mandate to be an enabler of cutting-edge life science research and innovation.

US Food & Drug Administration operates agencies to protect health and human services. It protects and promotes public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, cosmetics, animal foods and feed and veterinary products. The company was founded by Theodore Roosevelt and Harvey Washington Wiley on 30th June, 1906 and is headquartered in Silver Spring, MD.

National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD.

Q Therapeutics, Inc. engages in developing adult stem cell therapies to treat debilitating disease of the central nervous system. Its product, Q-Cells will undergo first-in-human trials for ALS. The firm’s therapeutic strategy is intended to restore the normal activity of neurons by providing the support functions present in healthy central nervous system tissue. The company was founded by Dennis B. Farrar, Mahendra S. Rao, Mani Ramaswami, and Steven Goldman on March 28, 2002 and is headquartered in Salt Lake City, UT.

Part of Pluristyx, Inc., panCELLa, Inc. is a privately held early-stage biotechnology firm based in Toronto, CA. panCELLa was acquired by Pluristyx, Inc. on October 06, 2022. panCELLa has secured partnerships with several biotechnology partners to enhance its patent position and provide expanded access to its exclusive failsafe™ and cloaked cells™/iact cells. The Canadian company continues its internal R & D efforts to develop additional novel uses of its platform technologies in areas such as bio-production, cancer vaccination, and tolerization. The company was founded in 2015 by Armand Keating and Andras Nagy, and has created platforms that allow for the development of safe, universal, cost-effective, “ off-the-shelf ” therapeutic cell products for medicine.

Q Therapeutic Products, Inc. develops novel products to treat debilitating and fatal diseases. The company was founded by Dennis B. Farrar and Mahendra S. Rao in 2004 and is headquartered in Salt Lake, UT.

Windgap Medical, Inc. engages in the development of epinephrine autoinjector for the treatment of anaphylaxis. The company was founded was founded by Christopher J. Stepanian and Brent Buchine and is headquartered in Somerville, MA.

New York State Society of Certified Public Accountants is a non-profit organization. It provides a membership program for certified public accountants that offers in-person and online networking opportunities, Continuing Professional Education courses and conferences, the CPA Journal, and other publications. The company was foudned in 1897 and is headquartered in New York, NY.

Part of Pluristyx, Inc., Implant Therapeutics is a Canadian biotechnology company that develops therapeutic products in the immunology, mesenchymal stem cell, and pancreatic islet space. The company partners with other companies to develop novel products in other areas of regenerative medicine. Under the guidance of Dr. Mahendra Rao, Implant Therapeutics engineers hypoimmunogenic and safe-harbor technologies in ipsc-msc and islets. These cells are an ideal choice for bone, cartilage, and tendon replacement strategies, combining the advantages of allogeneic and autologous cells, as well as allowing them to be used as ex-vivo gene therapy vehicles. The CEO of the company is Mahendra S. Rao.